A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma
Phase of Trial: Phase III
Latest Information Update: 24 Apr 2019
At a glance
- Drugs Denileukin diftitox (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eisai Inc
- 19 Apr 2019 Planned End Date changed from 30 Jun 2019 to 31 Dec 2019.
- 19 Apr 2019 Planned primary completion date changed from 30 Jun 2019 to 31 Dec 2019.
- 11 Jan 2019 Planned number of patients changed from 59 to 70.